Correlated species differences in the effects of cannabinoid ligands on anxiety and on GABAergic and glutamatergic synaptic transmission

European Journal of Neuroscience

Volumn 25, Issue 8, 2007, Pages 2445-2456

  Haller, J ^a   Matyas F ^a   Soproni, K ^a   Varga, B ^b   Barsy, B ^a   Nemeth B ^a   Mikics, E ^a   Freund, T F ^a   Hajos N ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b Richter Gedeon Plc   (Hungary)

Author keywords

AM 251; EPSC; IPSC; Mice; Rats; WIN 55, 212

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CHLORDIAZEPOXIDE; GLUTAMIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ARTICLE; BEHAVIORAL SCIENCE; CONTROLLED STUDY; CORRELATION ANALYSIS; ELECTROPHYSIOLOGY; EXCITATORY POSTSYNAPTIC POTENTIAL; GABAERGIC TRANSMISSION; INHIBITORY POSTSYNAPTIC POTENTIAL; MALE; MAZE TEST; MOUSE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RAT; SPECIES DIFFERENCE; SYNAPTIC TRANSMISSION; TRANQUILIZING ACTIVITY;

ANALGESICS; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BENZOXAZINES; CANNABINOIDS; CHLORDIAZEPOXIDE; EXCITATORY POSTSYNAPTIC POTENTIALS; EXPLORATORY BEHAVIOR; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; HIPPOCAMPUS; INHIBITORY POSTSYNAPTIC POTENTIALS; LIGANDS; MALE; MICE; MORPHOLINES; NAPHTHALENES; PATCH-CLAMP TECHNIQUES; PIPERIDINES; PYRAZOLES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; SYNAPTIC TRANSMISSION;

EID: 34247281666     PISSN: 0953816X     EISSN: 14609568     Source Type: Journal    
DOI: 10.1111/j.1460-9568.2007.05476.x     Document Type: Article

References (58)

1. Akinshola, B.E., Chakrabarti, A. & Onaivi, E.S. (1999) In-vitro and in-vivo action of cannabinoids. Neurochem. Res., 24, 1233-1240.
2. Arevalo, C., de Miguel, R. & Hernandez-Tristan, R. (2001) Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters. Pharmacol. Biochem. Behav., 70, 123-131.
3. Berrendero, F. & Maldonado, R. (2002) Involvement of the opioid system in the anxiolytic-like effects induced by Delta (9) - tetrahydrocannabinol. Psychopharmacology, 163, 111-117.
4. Bodor, A.L., Katona, I., Nyíri, G., Mackie, K., Ledent, C., Hájos, N. & Freund, T.F. (2005) Endocannabinoids signaling in rat somatosensory cortex: laminar differences and involvement of specific interneuron types. J. Neurosci., 25, 6845-6856.
5. Breivogel, C.S., Griffin, G., Di Marzo, V. & Martin, B.R. (2001) Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol. Pharmacol., 60, 155-163.
6. Darmani, N.A. (2001) Cannabinoids of diverse structure inhibit two DOI-induced 5-HT (2A) receptor-mediated behaviors in mice. Pharmacol. Biochem. Behav., 68, 311-317.
7. De Vry, J., Jentzsch, K.R., Kuhl, E. & Eckel, G. (2004) Behavioral effects of cannabinoids show differential sensitivity to cannabinoid receptor blockade and tolerance development. Behav. Pharmacol., 15, 1-12.
8. Felder, C.C., Joyce, K.E., Briley, E.M., Mansouri, J., Mackie, K., Blond, O., Lai, Y., Ma, A.L. & Mitchell, R.L. (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol. Pharmacol., 48, 443-450.
9. Ferrari, P.F., Palanza, P., Parmigiani, S. & Rodgers, R.J. (1998) Interindividual variability in Swiss male mice: relationship between social factors, aggression, and anxiety. Physiol. Behav., 63, 821-827.
10. File, S.E., Kenny, P.J. & Cheeta, S. (2000) The role of the dorsal hippocampal serotonergic and cholinergic systems in the modulation of anxiety. Pharmacol. Biochem. Behav., 66, 65-72.
11. Freund, T.F., Katona, I. & Piomelli, D. (2003) Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev., 83, 1017-1066.
12. Genn, R.F., Tucci, S., Marco, E.M., Viveros, M.P. & File, S.E. (2004) Unconditioned and conditioned anxiogenic effects of the cannabinoid receptor agonist CP 55,940 in the social interaction test. Pharmacol. Biochem. Behav., 77, 567-573.
13. Gifford, A.N., Bruneus, M., Gatley, S.J., Lan, R., Makriyannis, A. & Volkow, N.D. (1999) Large receptor reserve for cannabinoid actions in the central nervous system. J. Pharmacol. Exp. Ther., 288, 478-483.
14. Giuliani, D., Ferrari, F. & Ottani, A. (2000) The cannabinoid agonist HU 210 modifies rat behavioural responses to novelty and stress. Pharmacol. Res., 41, 47-53.
15. Griebel, G., Stemmelin, J. & Scatton, B. (2005) Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol. Psychiatry, 57, 261-267.
16. Hajos, N. & Freund, T.F. (2002) Pharmacological separation of cannabinoid sensitive receptors on hippocampal excitatory and inhibitory fibers. Neuropharmacology, 43, 503-510.
17. Hajos, N., Kathuria, S., Dinh, T., Piomelli, D. & Freund, T.F. (2004) Endocannabinoid transport tightly controls 2-arachidonoyl glycerol actions in the hippocampus: effects of low temperature and the transport inhibitor AM404. Eur. J. Neurosci., 19, 2991-2996.
18. Hajos, N., Katona, I., Naiem, S.S., Mackie, K., Ledent, C., Mody, I. & Freund, T.F. (2000) Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations. Eur. J. Neurosci., 12, 3239-3249.
19. Hajos, N., Ledent, C. & Freund, T.F. (2001) Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience, 106, 1-4.
20. Hájos, N., Mann, E.O., Freund, T.F. & Paulsen, O. (2005) Oxygen content of extracellular solution determines the stability of network oscillations in submerged hippocampal slices. Poster Number 275.18. Society for Neuroscience meeting, Washington.
21. Haller, J., Bakos, N., Szirmay, M., Ledent, C. & Freund, T.F. (2002) The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur. J. Neurosci., 16, 1395-1398.
22. Haller, J., Varga, B., Ledent, C., Barna, I. & Freund, T.F. (2004a) Context-dependent effects of CB1 cannabinoid gene disruption on anxiety-like and social behaviour in mice. Eur. J. Neurosci., 19, 1906-1912.
23. Haller, J., Varga, B., Ledent, C. & Freund, T.F. (2004b) CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents. Behav. Pharmacol., 15, 299-304.
24. Hill, M.N. & Gorzalka, B.B. (2004) Enhancement of anxiety-like responsiveness to the cannabinoid CB (1) receptor agonist HU-210 following chronic stress. Eur. J. Pharmacol., 499, 291-295.
25. Hoffman, A.F. & Lupica, C.R. (2000) Mechanisms of cannabinoid inhibition of GABA (A) synaptic transmission in the hippocampus. J. Neurosci., 20, 2470-2479.
26. Hoffman, A.F., Macgill, A.M., Smith, D., Oz, M. & Lupica, C.R. (2005) Species and strain differences in the expression of a novel glutamate-modulating cannabinoid receptor in the rodent hippocampus. Eur. J. Neurosci., 22, 2387-2391.
27. Janoyan, J.J., Crim, J.L. & Darmani, N.A. (2002) Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids. Pharmacol. Biochem. Behav., 71, 155-162.
28. Jarai, Z., Wagner, J.A., Varga, K., Lake, K.D., Compton, D.R., Martin, B.R., Zimmer, A.M., Bonner, T.I., Buckley, N.E., Mezey, E., Razdan, R.K., Zimmer, A. & Kunos, G. (1999) Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. U.S.A., 96, 14136-14141.
29. Katona, I., Rancz, E.A., Acsady, L., Ledent, C., Mackie, K., Hajos, N. & Freund, T.F. (2001) Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J. Neurosci., 21, 9506-9518.
30. Katona, I., Sperlagh, B., Sik, A., Kõfalvi, A., Vizi, E.S., Mackie, K. & Freund, T.F. (1999) Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J. Neurosci., 19, 4544-4558.
31. Katona, I., Urban, G.M., Wallace, M., Ledent, C., Jung, K.M., Piomelli, D., Mackie, K. & Freund, T.F. (2006) Molecular composition of the endocannabinoid system at glutamatergic synapses. J. Neurosci., 26, 5628-5637.
32. 3Hglutamate from rodent hippocampal synaptosomes via a novel CB1 receptor-independent action. Eur. J. Neurosci., 18, 1973-1978.
33. Kreitzer, A.C. & Regehr, W.G. (2001) Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron, 29, 717-727.
34. Ledent, C., Valverde, O., Cossu, G., Petitet, F., Aubert, J.F., Beslot, F., Bohme, G.A., Imperato, A., Pedrazzini, T., Roques, B.P., Vassart, G., Fratta, W. & Parmentier, M. (1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science, 283, 401-404.
35. Maccarrone, M., Valverde, O., Barbaccia, M.L., Castane, A., Maldonado, R., Ledent, C., Parmentier, M. & Finazzi-Agro, A. (2002) Age-related changes of anandamide metabolism in CB1 cannabinoid receptor knockout mice: correlation with behaviour. Eur. J. Neurosci., 15, 1178-1186.
36. Marco, E.M., Perez-Alvarez, L., Borcel, E., Rubio, M., Guaza, C., Ambrosio, E., File, S.E. & Viveros, M.P. (2004) Involvement of 5-HT1A receptors in behavioural effects of the cannabinoid receptor agonist CP 55,940 in male rats. Behav. Pharmacol., 15, 21-27.
37. Marin, S., Marco, E., Biscaia, M., Fernandez, B., Rubio, M., Guaza, C., Schmidhammer, H. & Viveros, M.P. (2003) Involvement of the kappa-opioid receptor in the anxiogenic-like effect of CP 55,940 in male rats. Pharmacol. Biochem. Behav., 74, 649-656.
38. Marsicano, G. & Lutz, B. (1999) Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur. J. Neurosci., 11, 4213-4225.
39. Martin, M., Ledent, C., Parmentier, M., Maldonado, R. & Valverde, O. (2002) Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology, 159, 379-387.
40. Mátyás, F., Freund, T.F. & Gulyás, A.I. (2004) Immunocytochemically defined interneuron populations in the hippocampus of mouse strains used in transgenic technology. Hippocampus, 14, 460-481.
41. McLaughlin, P.J., Lu, D., Winston, K.M., Thakur, G., Swezey, L.A., Makriyannis, A. & Salamone, J.D. (2005) Behavioral effects of the novel cannabinoid full agonist AM 411. Pharmacol. Biochem. Behav., 81, 78-88.
42. McNaughton, N. (1997) Cognitive dysfunction resulting from hippocampal hyperactivity - a possible cause of anxiety disorder? Pharmacol. Biochem. Behav., 56, 603-611.
43. Millan, M.J. (2003) The neurobiology and control of anxious states. Prog. Neurobiol., 70, 83-244.
44. Nakatsuka, T., Chen, H.X., Roper, S.N. & Gu, J.G. (2003) Cannabinoid receptor-1 activation suppresses inhibitory synaptic activity in human dentate gyrus. Neuropharmacology, 45, 116-121.
45. Navarro, M., Hernandez, E., Munoz, R.M., del Arco, I., Villanua, M.A., Carrera, M.R. & Rodriguez de Fonseca, F. (1997) Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport, 8, 491-496.
46. Nyíri, G., Cserép, C., Szabadits, E., Mackie, K. & Freund, T.F. (2005) CB1 cannabinoid receptors are enriched in the perisynaptic annulus and on preterminal segments of hippocampal GABAergic axons. Neuroscience, 136, 811-822.
47. Ohno-Shosaku, T., Tsubokawa, H., Mizushima, I., Yoneda, N., Zimmer, A. & Kano, M. (2002) Presynaptic cannabinoid sensitivity is a major determinant of depolarization-induced retrograde suppression at hippocampal synapses. J. Neurosci., 22, 3864-3872.
48. Pacher, P., Batkai, S. & Kunos, G. (2006) The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev., 58, 389-462.
49. Patel, S. & Hillard, C.J. (2006) Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J. Pharmacol. Exp. Ther., 318, 304-311.
50. Piomelli, D. (2003) The molecular logic of endocannabinoid signalling. Nat. Rev. Neurosci., 4, 873-884.
51. Rademacher, D.J., Patel, S., Hopp, F.A., Dean, C., Hillard, C.J. & Seagard, J.L. (2003) Microinjection of a cannabinoid receptor antagonist into the NTS increases baroreflex duration in dogs. Am. J. Physiol. Heart Circ. Physiol., 284, H1570-H1576.
52. Rodgers, R.J., Evans, P.M. & Murphy, A. (2005) Anxiogenic profile of AM-251, a selective cannabinoid CB1 receptor antagonist, in plus-maze-naive and plus-maze-experienced mice. Behav. Pharmacol., 16, 405-413.
53. Rodgers, R.J., Haller, J., Halász, J. & Mikics, É. (2003) 'One-trial sensitization' to the anxiolytic-like effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus-maze. Eur. J. Neurosci., 17, 1279-1286.
54. Rodriguez de Fonseca, F., Rubio, P., Menzaghi, F., Merlo-Pich, E., Rivier, J., Koob, G.F. & Navarro, M. (1996) Corticotropin-releasing factor (CRF) antagonist [D-Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats. J. Pharmacol. Exp. Ther., 276, 56-64.
55. Seagard, J.L., Dean, C., Patel, S., Rademacher, D.J., Hopp, F.A., Schmeling, W.T. & Hillard, C.J. (2004) Anandamide content and interaction of endocannabinoid?GABA modulatory effects in the NTS on baroreflex-evoked sympathoinhibition. Am. J. Physiol. Heart Circ. Physiol., 286, H992-H1000.
56. Uriguen, L., Perez-Rial, S., Ledent, C., Palomo, T. & Manzanares, J. (2004) Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors. Neuropharmacology, 46, 966-973.
57. Valjent, E., Mitchell, J.M., Besson, M.J., Caboche, J. & Maldonado, R. (2002) Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine. Br. J. Pharmacol., 135, 564-578.
58. Zimmer, A., Zimmer, A.M., Hohmann, A.G., Herkenham, M. & Bonner, T.I. (1999) Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A., 96, 5780-5785.